Swiss biotechnology Cytos announced that New York-based Pfizer Inc. has agreed to pay $140 million dollars to acquire world-wide exclusive rights to market vaccines, based on Cytos biotech Immundrug technology.

Although specific details of the agreement were not revealed, the deal was closed past August. Back then Pfizer agreed to make an upfront payment of $9.15 million dollars with the possibility of a total deal of $130 million dollars if clinical objectives are achieved and exclusive rights to use Cytos biotech Immundrug technology.

The deal also comprises manufacturing technology transfer fees, and Cytos will be eligible for research funding and royalties of 10 percent on net sales of products.

The exclusive global research, option and license agreement aims to research, develop, manufacture and market vaccines for a defined number of human diseases, Cytos stated.

Even though the agreement was closed last August, Pfizer deferred the payment until now.

The Schlieren company, which currently has five drug candidates in clinical-stage trials, is in partnerships with Novartis to develop nicotine addiction and Alzheimer's disease treatments. Cytos is also studying other compounds to replace daily-dose needs of tablets ingestion on hypertension patients.